| Document |
Document Title |
|
WO/1995/034571A2 |
It has been found that sugar acid salts represent beneficial controlled release forms for basic organic drug compounds. Examples of appropriate salts include mono, di, oligo and polysaccharide poly-O-sulphonic acid salts of antibiotics s...
|
|
WO/1995/023807A1 |
Novel pseudoceramides of formulae (Ia) and (Ib) are proposed, (Ia) (Ib) in which R1 stands for a linear or branched alkyl and/or alkenyl residue having 6 to 30 carbon atoms, Y stands for oxygen or an NR5 group, R2 stands for hydrogen or ...
|
|
WO/1995/021850A1 |
Methods are provided for generating highly diverse mixtures of compounds which may be screened for biological activities. Once the activity is found, the component of the mixture which is responsible for the activity can be isolated by f...
|
|
WO/1995/017903A1 |
The design and synthesis of novel oxazolone-derived molecular modules and the use of the modules in the construction of new molecules and fabricated materials is disclosed. The new molecules and fabricated materials are molecular recogni...
|
|
WO/1995/015309A1 |
Compounds selected from those of general formula [A-B (Groups I and II)] and (group III), (1, 2 and 3) where B is (4) and A is selected from specified aminoacyl compounds are inhibitors of DP-IV mediated processes.
|
|
WO/1995/014028A2 |
Novel methods for the treatment and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and ...
|
|
WO/1995/014026A1 |
The invention relates to 'beta'(1}6) glucosamine disaccharides having general formula (I) to a method for preparing these disaccharides, comprising the steps of: i) providing a starting material comprising lipid A moiety of lipopolysacch...
|
|
WO/1995/007700A1 |
A method for protecting against mutational damage in mammalian cells induced by irradiation comprising administering a phosphorothioate or phosphorothioate metabolite to the mammal before or up to 3 hours after irradiation.
|
|
WO/1995/007914A1 |
The present invention relates to novel amino glycoside salts of sucrose-octa-O-sulfonic acid having the general formula (I): ([sucrose-octa-O-sulfonic acid8-]-[R-(NH3+)x]y-Mzn+), wherein (x . y) + (z . n) = 8, x . y N|[4 x . y 8], N is t...
|
|
WO/1994/026756A1 |
Fluoro-compounds are made by reaction of an activated oxy-acid ester or cyclic ether starting material with hydrogen fluoride in the presence of an organometallic compound.
|
|
WO/1994/022837A1 |
The application concerns a biologically active compound obtained by chemical synthesis and belonging to the class of heterocyclic compounds (specifically, the secondary acridones), namely: N-methyl-N-/alpha,DELTA-glucopyranozil/ammonia-2...
|
|
WO/1994/021653A1 |
A method is provided for preparing [18F]2-fluoro-2-deoxyglucose with an anion exchange resin by effecting an exchange reaction between an aqueous solution of [18F]fluoride containing an alkali metal carbonate or bicarbonate, such as sodi...
|
|
WO/1994/015623A1 |
This invention includes a pharmaceutical composition including a pharmaceutically acceptable carrier, urea, and hyaluronic acid or a pharmaceutically salt thereof. The invention also includes a method of treating disease of the cutis whi...
|
|
WO/1994/011006A1 |
Substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, including compositions containing same and methods of using same, are disclosed for the regulation of cytokine activity in a host. For in...
|
|
WO/1994/011381A1 |
Compounds of this invention are derivatives of pentose monosaccharides which exhibit anti-proliferative and anti-inflammatory activity as well as intermediates for the synthesis of these compounds. Methods of preparation, pharmaceutical ...
|
|
WO/1994/002624A1 |
An enzymatic process is disclosed for the preparation of galactosylbeta1,3glycal disaccharides such as Galbeta1,3Glucal, an intermediate useful in Lea preparation and an inhibitor of beta-galactosidase. The process utilizes beta-galactos...
|
|
WO/1993/024505A1 |
Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammal. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type Ii core structure w...
|
|
WO/1993/024506A1 |
Disclosed are novel Lewis?C¿ and LacNAc analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.
|
|
WO/1993/023163A1 |
Acid catalysts are prepared by reacting short-chain triglycerides having the formula (I), in which R?1¿, R?2¿ and R?3¿ represent independently from each other alkyl rests with 1 to 4 carbon atoms, with sulphur trioxide. These catalyst...
|
|
WO/1993/017689A1 |
A method and pharmaceutical for protecting against genotoxic damage in irradiated cells. Reduction of mutations at the hypoxanthine-guanine phosphoribosyl transferase locus is accomplished by administering an effective dose of a compound...
|
|
WO/1993/016087A2 |
Novel Amadori reaction compounds have the formula R¿1?-NH-R¿2?, wherein R¿1? comprises the D-form of a 1-amino-1-deoxy-2-ketose radical derived from a sugar radical selected from the group of glucose, xylose, galactose, rhamnose, fruc...
|
|
WO/1993/011776A1 |
O-glycosylation and O-glycosylation extension inhibitors influence selectin-dependent interactions between cells and between cells and platelets.
|
|
WO/1993/010796A1 |
Simple lactose or lactosamine related compounds which behave as ligands for the ELAM-1 and related receptors are described. These compounds are of formula (1) wherein each R1 is independently H or lower alkyl (1-4C); R2 is H, lower alkyl...
|
|
WO/1993/010137A1 |
2'-Deoxy-2'-fluorocoformycin and 2'-deoxy-8-epi-2'-fluorocoformycin have now been synthesized by a multistage reaction via 3,5-di-O-benzoyl-2-deoxy-2-fluoro-alpha- and -beta-D-ribofuranosyl bromide. Also 2'-deoxy-2'-epi-2'-fluorocoformyc...
|
|
WO/1993/008205A1 |
This invention contemplates improved methods of enzymatic production of carbohydrates especially fucosylated carbohydrates. Improved syntheses of glycosyl 1- or 2-phosphates using both chemical and enzymatic means are also contemplated. ...
|
|
WO/1993/003004A1 |
Amines such as methyl amine are reacted with materials such as reducing sugars in aqueous/hydroxy solvents such as water and/or methanol to prepare N-alkyl polyhydroxy amines. Accordingly, glucose is reacted with methyl amine and the res...
|
|
WO/1993/002091A1 |
Broad spectrum glycosidase inhibitors are produced from monosaccharide lactams by conversion to amidines, amidrazones, or amidoximes. The inhibitors have general formula (I), wherein the N and C are joined as part of a monosaccharide aza...
|
|
WO/1992/022662A1 |
Disclosed are methods for the preparation of monofucosylated and sialylated derivatives of the compound $g(b)Gal(1-4)$g(b)GlcNAc(1-3)$g(b)Gal(1-4)$g(b)GlcNAc-R. In particular, the methods of this invention provide for a multi-step synthe...
|
|
WO/1992/022301A1 |
Disclosed are methods of and pharmaceutical compositions for suppressing cell-mediated immune responses including cell-mediated inflammatory responses. The disclosed methods and compositions employ oligosaccharide glycosides.
|
|
WO/1992/019632A1 |
The present invention discloses trifluorofucoses and methods of making the same. Also disclosed are trifluorofucose analogs of fucose-containing oligosaccharides, and conjugates of trifluorofucose. The compounds of the present invention ...
|
|
WO/1992/014743A2 |
A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable deriva...
|
|
WO/1992/008790A1 |
Polymer protein compounds, which include a polymer, such as a polyvinyl polymer, acrylic polymer, polyester polymer or polyamide polymer having a main chain, a linker which separates the polymer from the protein by at least two carbons, ...
|
|
WO/1992/003472A1 |
The present invention provides novel peptides. These peptides have a novel non-cleavable transition state insert corresponding to the 10,11-position of the renin substrate (angiotensinogen) of formula (XL8). These peptides are useful as ...
|
|
WO/1992/002527A1 |
Ligands that bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. These ligands have the formula (I) wherein each of the saccharide rings shown is connected at its 1-position to the next saccharide at its 3-position ...
|
|
WO/1992/000308A1 |
Process for producing acylated glycosyl fluorides by the fluoridation of saccharides which are at least partly O-acylated in non-aqueous hydrogen fluoride in which the corresponding carboxylic acid anhydride is added to the hydrogen fluo...
|
|
WO/1991/015496A1 |
An essentially pure substance has a structure of a Nod factor or one of its analogues. The Nod factor is characterized by the fact that its biosynthesis is controlled by at least one nodulation gene (nodA,B,C) common to the Rhizobiaceae,...
|
|
WO/1991/015497A1 |
In a process for producing a concentrated, stable solution of a lactose derivative from an aqueous solution containing lactose monohydrate, a chemical compound such as an alcohol capable of reacting with one of the two OH functions of th...
|
|
WO/1991/012824A2 |
19F labelled compounds are disclosed which are useful in methods of NMR imaging and spectroscopy. The compounds comprise a 19F-containing sensor moiety, and a transport polymer or substrate, and can optionally also comprise a spacer moie...
|
|
WO/1991/010672A1 |
The invention provides compounds of formula (I) wherein R?1� represents alkyl, R?2� represents an acid-labile protecting group and X?1� represents a halogen atom, which are useful in the synthesis of mevalonic acid derivatives.
|
|
WO/1991/002530A1 |
An accelerator for periodontal tissue regeneration comprising as the active ingredient an N-acetylated amino sugar selected from the group consisting of N-acetyl-D-glucosamine, N-acetly-D-galactosamine, N-acetyl-D-mannosamine, and oligos...
|
|
WO/1991/001326A1 |
Pyrimidine 4'-thionucleosides of formula (I), wherein Y is hydroxy or amino, and X is chloro, bromo, iodo, trifluoromethyl, C2-6 alkyl, C2-6 alkenyl, C2-6 haloalkenyl or C2-6 alkynyl and physiologically functional derivatives thereof. Th...
|
|
WO/1990/014350A1 |
A process for producing 1-fluoro-glycuronic acids which may contain protected amino groups and their salts, in which glycopyranosylfluorides of mono or oligo-saccharides with at least one primary OH function are oxidised in aqueous solut...
|
|
WO/1990/010023A1 |
A copolymer of an N-acylated glycosylamine and an amide having general formula (I), wherein R2 is a reducing sugar residue; R3 is H or CH3; x is an integer from 0 to about 20; and m is such that the molecular weight of the copolymer is f...
|
|
WO/1990/008549A1 |
N-acetylglucosamine preparations for oral administration, used to treat degenerative and inflammatory diseases of the articulations and of the connective tissue and stroma, and related diseases.
|
|
WO/1990/002132A1 |
Constituents of the non-protein-nitrogen fraction of untreated raw milk or fresh milk have a characteristic pharmacological activity.
|
|
WO/1989/010373A1 |
Chemical compounds characterized by formula (I) wherein R1 is hydrogen or optionally substituted alkyl, R2 is hydrogen, and optionally substituted alkyl or a radical derived from the hydroxyl function and n is comprised between 0 and 7 p...
|
|
WO/1989/008845A1 |
Antibodies, specific for N-glycane structures of cell membrane surfaces and which, in an immunoassay, for example RIA and ELISA assay, or microtiter plates, exhibit a positive reaction to antigen oligosaccharides with structural elements...
|
|
WO/1989/007602A1 |
Anion exchange resins which have been exchanged with molybdate at acid pH are effective catalysts for epimerizing compounds with structural unit (I). Chief among these are aldoses, especially aldopentoses and aldohexoses, as well as some...
|
|
WO/1989/003672A1 |
The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, netilmycin and amphotericin B, administered by precise sprayin...
|
|
WO/1989/003673A1 |
The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, tobramycin and amphoterycin B, administered by precise sprayin...
|
